The phosphoinositide 3-kinase (PI3K) pathway, with downstream targets including Akt and mammalian target of rapamycin, has been implicated in numerous human cancers, including hematologic malignancies and lymphomas. The development and refinement of PI3K inhibitors directed toward this pathway show promising clinical efficacy. This review will discuss the emerging body of clinical data in lymphoid malignancies and present future directions for research utilizing these inhibitors.
INTRODUCTION
Given the complexity of B-cell lymphoproliferative disorders, there is an urgent need to find common aberrant pathways for therapeutic targeting among lymphoma subtypes. One recently identified key element in lymphomagenesis and pathogenesis is B-cell receptor (BCR) signaling, which is required for both malignant and nonmalignant mature B-cell survival. The BCR is a ubiquitous surface protein complex with a number of intracellular signaling components. One of the most proximal signaling nodes is phosphoinositide 3-kinases (PI3Ks), a highly conserved family of intracellular lipid kinases that regulate critical cellular processes, including proliferation, growth, apoptosis and cytoskeletal rearrangement [1] . In addition to mediating BCR signaling, PI3K integrates signals from a variety of other chemokines and cytokines and has multiple downstream intracellular effects on Akt, mammalian target of rapamycin (mTOR) and NF-kB.
The PI3K family is categorized into three classes, grouped into classes I, II and III, on the basis of substrate preference and sequence homology. Class I PI3Ks, the most widely implicated in human neoplasia [2] , are further divided into two subgroups, class IA and class IB (Fig. 1) , with class IA PI3Ks activated by growth factor receptor tyrosine kinases, and class IB PI3Ks activated by G-protein coupled receptors [1, 2] . Binding of the class IA p85 regulatory subunit to receptor tyrosine kinases relieves the inhibition of the p110 catalytic subunit, resulting in conversion of phosphatidyl inositol (PIP)2 to PIP3. PIP3 assists in phosphorylation of Akt, which promotes cell growth and survival by a variety of downstream mechanisms, including inhibition of proapoptotic Bcl-2 family members, decreased negative regulation of the NF-kB transcription factor, inhibition of p53-mediated apoptosis and stimulation of the mTOR [3] . Phosphatase and tensin homolog (PTEN), which removes the 3-phosphate from PIP3 and thus down-modulates Akt signaling, is a major negative regulator of the PI3K/ Akt/mTOR pathway [4, 5] .
The PI3K pathway is constitutively deregulated in multiple malignancies and overexpression of the class I p110 isoforms (p110a, p110b, p110d, p110g) has been shown to induce oncogenic transformation in cell culture [6] . Among the PI3K isoforms, PI3Ka mutations are the most widely implicated in human cancer. Gain of function mutations in the gene encoding PI3Ka occurs frequently in human tumors [7, 8] , and cancer cell line models have shown correlation between PI3Ka mutations and sensitivity to PI3K inhibitors [9] . The role of PI3Kb in human cancers is less clear and PI3Kg, although highly expressed in leukocytes, may play a more crucial role in the immune system than in oncogenesis [9] .
Among the PI3K isoforms, PI3Kd may be the most important in hematologic malignancies. PI3Kd and the p110d isoform are highly expressed in lymphocytes and lymphoid tissues [10, 11] . In B-cell malignancies, aberrant PI3K signaling may be the result of constitutive BCR activation and/or response to proliferation and survival factors present in the bone marrow and lymph node microenvironments [12] [13] [14] [15] [16] . PI3Kd signaling appears to be critical for activation, proliferation and survival of B-cells and plays an important role in homing and retention in lymphoid tissues. Pharmacologic approaches that specifically inactivate p110d demonstrate its central role in B-cell signaling [17] [18] [19] , making it an attractive target for treatment of hematologic malignancies, especially B-cell malignancies.
TARGETING THE PHOSPHOINOSITIDE 3-KINASE PATHWAY
Emerging awareness of the PI3K pathway's role in hematologic malignancies has prompted a concerted effort to develop targeted PI3K inhibitors. First-generation PI3K inhibitors, wortmannin and LY294002, had broad activity in vitro and inhibited all four PI3K isoforms, but due to unfavorable pharmaceutical properties and limited single-agent in-vivo efficacy, were not developed further for clinical use [20] . These compounds were also found to lack specificity and inhibit multiple other kinases [9] , fueling the search for more targeted PI3K inhibitors, including the development of PI3K inhibitors against specific isoforms. There is a robust body of preclinical data of PI3K inhibitors in lymphoid malignancies supporting the proliferation of ongoing single agent and combination clinical trials, with several detailed reviews available. Here, we summarize the clinical data to date of PI3K inhibitors in lymphoid malignancies, focusing mainly on idelalisib, a PI3Kd inhibitor, and IPI-145, a dual PI3Kd or PI3Kg inhibitor, which are furthest along in development.
Chronic lymphocytic leukemia
Idelalisib is, to date, the most well studied of the PI3Kd inhibitors in hematologic malignancies. Previously known as CAL-101 or GS-1101, idelalisib is a potent selective p110d inhibitor and, in primary cells from patients with lymphoid and myeloid leukemias, has been shown to block PI3K signaling, resulting in decreased phosphorylation of Akt and induction of apoptosis [21, 22] . Chronic lymphocytic leukemia (CLL) tumor cells have higher intrinsic PI3K activity compared with normal B-cells [22] , and promising preclinical data of idelalisib in CLL, including dose-dependent cytotoxicity, reduction of survival signals from the BCR, abrogation of protective microenvironment stimuli and
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A recently published pivotal phase I trial in CLL evaluated escalating doses of idelalisib in 54 adult patients with relapsed or refractory CLL requiring therapeutic intervention [24 & ]. The patients had many adverse risk features, including high-risk Rai stage disease at presentation (67%), bulky lymphadenopathy (80%), unmutated IGHV (91%) and del17p or TP53 mutations (24%). Patients were also heavily pretreated, with a median of five prior therapies (range 2-14). All patients had received fludarabine, nearly all patients (96%) had received rituximab, and the majority of the patients (87%) had been treated with alkylating agents. Idelalisib was generally well tolerated, with most adverse events related to the underlying disease or previous therapy. Serious adverse events included pneumonia (20%), febrile neutropenia (9%), colitis (6%), cellulitis (6%) and pseudomonas bacteremia (6%). One fairly unique toxicity is transient transaminase elevation, with transaminase elevations of any grade seen in 28% of patients in this study. Despite the level of elevation, the transaminases typically showed rapid resolution with holding idelalisib. The investigators comment that idelalisib could be safely restarted in most patients with a dose reduction. Other drug-related events included skin rashes and diarrhea. While response was not the main outcome of this study, idelalisib demonstrated promising results, with 44 of 54 patients (81.5%) achieving a lymph node response of greater than 50% and an overall response rate of 72%. The median progression-free survival was 15.8 months and the median overall survival was not reached. Notably, among patients with deletion 17p and/or TP53 mutation, the overall response rate was 54% (7 of 13 patients), with median progression-free survival of 3 months. No dose-limiting toxicities were reached, and the dose for further investigation was determined to be 150 mg twice daily.
Given the single-agent activity and overall tolerable side-effect profile, idelalisib has entered a number of combination studies. Preliminary results from a phase I trial of idelalisib, combined with rituximab and/or bendamustine in patients with relapsed or refractory CLL, were initially presented in 2011 [25] . Among 27 patients enrolled at the time, over three-fourths of patients had a 50% or greater decrease in lymph node area. This decrease in lymphadenopathy occurred on all three regimens and generally within the first two cycles of treatment. In updates presented at both the American Society of Hematology and the American Society of Clinical Oncology annual meetings, over 50 patients had been enrolled. In this group of patients, of which half had refractory disease, the overall response rate was 81%, with a 2-year progressionfree survival and overall survival of 62 and 85%, respectively [26, 27] . The authors concluded that all three combination regimens were highly active and resulted in durable tumor control in patients with heavily pretreated relapsed or refractory CLL.
A phase III randomized, double-blind, placebocontrolled trial of rituximab in combination with idelalisib versus placebo was recently completed in 220 patients with relapsed CLL [28 && ]. The patients enrolled in the trial had progressed within 24 months of their last treatment and were not able to receive cytotoxic agents because of severe neutropenia or thrombocytopenia, renal insufficiency or significant coexisting illnesses (score on the Cumulative Illness Rating Scale of more than six). The majority (84%) of patients had unmutated IGHV and nearly half (44%) had 17p deletion or TP53 mutation. The study was stopped early because of apparent efficacy and, at the time of analysis, showed significantly increased progression-free survival (5.5 months in placebo group versus not reached in idelalisib group), improved overall response (13% in placebo group versus 81% in idelalisib group) and significantly increased overall survival at 12 months (P ¼ 0.02). When patients were stratified according to 17p deletion, TP53 mutation and IGHV mutation status, the improvement in progression-free survival with idelalisib persisted. Similar to the phase I trial, idelalisib was well tolerated, with adverse events including aminotransferase elevations, rash and diarrhea, but there was no overall increase in the rate of adverse events in the group receiving idelalisib as compared with placebo. On the basis of these data, the Food and Drug Administration (FDA) granted idelalisib breakthrough therapy designation and a new drug application for the treatment of CLL was submitted to the FDA in December 2013.
There is also clinical interest in combining idelalisib with other agents. For instance, a phase I study of idelalisib in combination with rituximab or ofatumumab in patients with relapsed or refractory CLL demonstrated high activity, with over 80% overall response rate, and acceptable safety profiles [29] . A phase III trial is currently underway in patients with previously treated CLL, randomized to receive ofatumumab, with or without idelalisib (NCT01659021) [30] . In patients with CLL, lenalidomide can induce tumor flare and cytokine release, which may promote CLL survival and is dependent on the PI3K p110d pathway [31] . Thus, clinical trials combining lenalidomide and idelalisib are underway.
It is important to note that a transient lymphocytosis was seen across all studies of idelalisib in CLL. For instance, in phase I trials, an increase in peripheral absolute lymphocyte counts of greater than 50% was observed in over half of patients [24 & ,32,33] . This increase peaked at 2 months and then gradually declined. This transient lymphocytosis was similarly noted in the recently published phase III trial of rituximab and idelalisib, although the addition of rituximab appeared to shorten the duration, with the peak of lymphocytosis at week 2 and resolving by week 12 [28 && ]. Prior studies demonstrated that idelalisib normalized plasma concentrations of CCL3, CCL4 and CXCL13. Because chemokines, especially CXCL13, appear to be important for CLL cells to home to lymphatic tissues, it has been hypothesized that this transient increase in peripheral lymphocytes is related to interference of idelalisib with the normal B-cell migration and homing to lymphatic tissues [23] . Thus, these data suggest that, in clinical use and studies of idelalisib, early transient lymphocytosis should not be confused with progression.
Like idelalisib, IPI-145 is a potent inhibitor of PI3Kd, but is also a potent inhibitor of PI3Kg. A phase I, dose-escalation study of IPI-145 is currently underway in patients with advanced hematologic malignancies, including a subset of 44 patients with relapsed or refractory CLL, and the interim analysis was presented in 2013. IPI-145 was well tolerated, with the most common adverse events being transient neutropenia, anemia and pneumonitis, and in this subgroup of heavily pretreated CLL patients, many (44%) with TP53 mutation and/or 17p deletions, IPI-145 demonstrated promising clinical activity, with an overall response rate of greater than 50% [34] .
Indolent non-Hodgkin lymphoma
Idelalisib is also actively being studied as a therapy for indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma, small lymphocytic lymphoma or leukemia, marginal zone lymphoma and lymphoplasmacytic lymphoma. In a phase I study of 64 patients with relapsed iNHL, idelalisib was well tolerated and clinically active, with an overall response rate of 47% in this patient population [35 & ]. A phase II trial of 125 relapsed patients with iNHL refractory to rituximab and an alkylating agent again showed clinical activity, with an overall response rate of 57%, and an acceptable safety profile, with the most common adverse grade 3 or greater adverse events being neutropenia, aminotransferase elevations, diarrhea and pneumonia [36 && ]. On the basis of this study, a new drug application was submitted to the FDA for the use of idelalisib in refractory iNHL.
Combination studies of idelalisib and other agents are underway in iNHL. A phase I trial of patients with heavily pretreated iNHL combined idelalisib with rituximab and/or bendamustine. The overall response rate was 81%, with 28% of patients overall achieving a complete response (43% complete response in the group receiving all three drugs). Adverse events were similar to those seen with idelalisib as single-agent therapy. The authors concluded that idelalisib-based combination therapy is highly active and well tolerated in patients with relapsed or refractory iNHL [37] . Phase III trials are currently ongoing.
Early reports from phase I trials of IPI-145 in relapsed or refractory lymphoma have shown clinical efficacy and an acceptable safety profile, with the most common adverse events being neutropenia and transaminase elevations, as seen with idelalisib [38] . A large phase II multicenter clinical trial is currently underway (NCT01882803, Table 1 ). Although PI3K may also be important in aggressive lymphomas, there are no substantial data to date in those subsets.
Mantle cell lymphoma
On the basis of gene expression profiling, the PI3K or AKT signaling pathway appears to be upregulated in mantle cell lymphoma (MCL) cells compared with naïve B cells [39] , and inhibition of PI3K decreases growth and induces apoptosis in MCL cell lines [40] . Thus, this pathway may also be a useful therapeutic target in MCL. A phase I trial of 40 patients with relapsed or refractory MCL demonstrated tolerable adverse effects, with the most common grade 3 or greater effects including diarrhea (18%), decreased appetite (15%), pneumonia (10%) and transaminase elevations (20%). The overall response rate was 40%, with a complete response in two patients (5%) [41 & ] . A separate phase I study combining idelalisib with everolimus, bortezomib, or rituximab plus bendamustine in 22 patients with relapsed or refractory MCL demonstrated an overall response rate of 46%, with two achieving complete response (9%). All of the combinations appeared to be tolerable [42] . These trials have suggested that idelalisib is a viable treatment strategy in patients with MCL, and further studies are underway.
The dual PI3Kd and PI3Kg inhibitor IPI-145 has also been studied in MCL in the same phase I study mentioned in iNHL [38] . In the small subset of six evaluable patients, there was a 67% overall response rate, with one patient achieving a complete response. Further studies are ongoing.
Other lymphomas
Although most trials have evaluated PI3K inhibitors as a downstream component of BCR signaling, there are clearly important functions of PI3K independent of this role. For instance, high levels of PI3Kd have been detected in Hodgkin lymphoma cell lines and, in preclinical studies, idelalisib resulted in inhibition of Akt phosphorylation and induced dosedependent apoptosis [43] . Similarly, there are data that PI3K inhibitors may also be effective in T-cell lymphomas as well. Among eight patients with T-cell lymphoma and evaluable disease treated with IPI-145, one had a complete response, and two had partial response [44] . Treatment-related adverse events occurred in half of the patients, with the most common grade 3 or greater adverse events being increased alanine aminotransferase, rash and pneumonia.
OTHER PHOSPHOINOSITIDE 3-KINASE INHIBITORS
In addition to idelalisib and IPI-145, there are multiple other PI3K inhibitors in active development for hematologic malignancies (see Table 1 ). AMG319, a PI3Kd inhibitor, has demonstrated promising preclinical activity against various lymphoma cell lines [45] and is currently under study in a phase I trial in patients with relapsed or refractory lymphoid malignancies. Another PI3Kd inhibitor, TGR-1202, was designed specifically to attempt to mitigate the hepatotoxicity that occurs with this class of agent. TGR-1202 is also currently being studied in a phase I trial in patients with relapsed or refractory hematologic malignancies and preliminary reports of the 13 patients treated thus far demonstrated minimal toxicity, with no hepatotoxicity aside from a grade 1 elevated gammaglutamyl transpeptidase [46] . NVP-BKM120, which has been shown to inhibit all four class I PI3K isoforms [47] , induces cell death in Burkitt lymphoma [16] and CLL [15] cell lines, as well as sensitizing CLL cells to bendamustine and fludarabine and disturbing the protective effect of the tumor microenvironment [15] . It is being studied in phase I trials both as a single agent and in combination with rituximab.
CONCLUSION
An unresolved question is whether isoform-specific targeting will be sufficient for treatment of hematologic malignancies, or if dual PI3K or mTOR inhibitors or the combination of PI3K with chemotherapeutic agents will be necessary. Although idelalisib shows activity as a single agent, it may be more effective when combined with standard chemotherapy, as is being demonstrated in current clinical trials. Much less is known about intrinsic or acquired resistance to PI3K inhibitors. Further research will need to focus not only on the design of additional targeted PI3K inhibitors, but also on the ideal combinations of agents that may abrogate resistance.
It is of interest that in both CLL and lymphoma, the PI3K inhibitors appear to exert some of their action through the microenvironment and via blockade of BCR signaling, rather than directly affecting the tumor cells. There is yet much to learn and understand about these pathways, but studies thus far support the microenvironment as an important target for therapeutics. On the basis of the encouraging preclinical and early clinical data, inhibition of the PI3K pathway appears to be a promising new therapeutic target in hematologic malignancies, especially in B-cell malignancies. This field is rapidly expanding, with many new agents currently being developed, and understanding of this pathway will become increasingly important.
